Please assess the completion status of the following clinical trial:

Trial Title: Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Patients diagnosed as having systemic JIA based on the International League of Associations for Rheumatology criteria (1997)~* Patients between 2 and 19 years of age~* Patients who are under 16 years of age at onset~* Patients who have been treated with corticosteroids (continued treatment for 3 months or longer at a dose of ≥0.2 mg/kg as prednisolone equivalent) but who failed to respond adequately or in whom treatment could not be continued or the dose could not be increased due to adverse drug reactions~Exclusion criteria~* Patients who have been treated with infliximab or etanercept within 12 weeks before treatment with the investigational product~* Patients who have received the following treatments within 4 weeks before treatment with the investigational product~  1. Surgical treatment (e.g., operation)~ 2. Plasma exchange therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).